Phase I Study on the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Subcutaneous Injection of SHR-2173 in Healthy Subjects

NCT06995001 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

35

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Volunteers

Interventions

DRUG: SHR-2173
DRUG: SHR-2173 ；Placebo
DRUG: SHR-2173 ；Placebo
DRUG: SHR-2173 ；Placebo
DRUG: SHR-2173 ；Placebo

Sponsor

Guangdong Hengrui Pharmaceutical Co., Ltd